Comparison of the effect of melatonin and plerixafor on the number of isolated stem cells in autologous transplant patients

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) has become the standard of care in patients with relapsed aggressive NHL and symptomatic MM. The success of HDT/ASCT depends on the pool of hematopoietic stem cells for transplantation. Belarixafor and granulocyte growth stimulating factor play an essential role in stimulating proliferative cells. In this discussion, we want to examine the role of melatonin. Implementation method: In this study, we studied 112 patients in three groups, the first group received only GCSF, the second group received GCSF and belarixafor. The third group received GCSF and melatonin. The average age of the patients was 48+11.67. These patients were examined in terms of the number of proliferative cells and mononuclear cells, the day of engraftment, the level of albumin and lactate dehydrogenase, and the presence of fever. Results: There was no significant difference in the amount of CD34 hyperproliferative cells in the three groups, but the average of the melatonin group was slightly higher than the GCSF alone group. Regarding the proliferation of mononuclear cells between the GCSF alone group and the melatonin group, and the absence of fever in Belrixafor and the presence of fever There was only a significant difference in GCSF. And there was a significant difference between berixafor and melatonin on the day of engraftment. In the discussion of melatonin engraftment, their engraftment was faster. The albumin level between melatonin and GCSF had only a significant difference, and the albumin of the melatonin group was higher.